Patents by Inventor Erik Ian Tucker

Erik Ian Tucker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200054719
    Abstract: According to the invention, a novel combination composition and method of treatment for thrombotic disorders, e.g., STEMI in ACS patients, is disclosed. The present invention relates to thrombin analogs, e.g., WE and E-WE thrombin analogs, in combination with fibrinolytics, e.g., tPA. In particular, E-WE thrombin analog and fibrinolytic combination therapy for inhibition of thrombin mediated TAFi activation and acceleration of tPA induced thrombolysis with E-WE thrombin. The present invention also relates to methods of treating a subject having a thrombotic or thromboembolic disorder by delivering the novel composition comprised of at least one antithrombotic thrombin analog and at least one fibrinolytic agent to the subject.
    Type: Application
    Filed: November 2, 2017
    Publication date: February 20, 2020
    Inventors: Erik Ian Tucker, Brandon Davis Markway, Michael Nikolaus Wallisch, Nora Green Verbout
  • Patent number: 8399648
    Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: March 19, 2013
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
  • Publication number: 20120276112
    Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: April 13, 2012
    Publication date: November 1, 2012
    Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
  • Patent number: 8236316
    Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 21, 2008
    Date of Patent: August 7, 2012
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani
  • Publication number: 20110020349
    Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Application
    Filed: November 21, 2008
    Publication date: January 27, 2011
    Inventors: Andras Gruber, Erik Ian Tucker, Stephen Raymond Hanson, David Gailani